momentum, page-9

Southoz, thanks for detailed analysis.
I have no medical knowledge and can't comment on the medical perspective.

I rely on the company's announcement,
"
The FDA previously confirmed that the Company’s Combination Rule Trial, Study 008, satisfied efficacy requirements and that there were no efficacy or safety issues identified in any of the studies submitted in the original NDA.
QRxPharma completed an audit of the more than 30 million data points for oxygen desaturation from Study 022. We believe these data demonstrate a significant respiratory safety advantage for MOXDUO over equi-analgesic doses of morphine or oxycodone. Furthermore, MOXDUO provides a lower starting dose and finer dose titration steps than acute pain opioids presently available, giving greater flexibility to physicians and patients as the need for pain relief is balanced with lower risks of side effects."

Also, few institutional reports also show confidence on the approval of Moxduo in May. They have come up with a valuation over $2.50. I would take half profit around $1.20, then wait and see.